Dr. Pegram on Challenges Facing the Treatment of HER2-Positive Breast Cancer

Mark D. Pegram, MD
Published: Friday, Sep 01, 2017



Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Safety signals remain to be a big challenge facing this patient population, explains Pegram. While TKIs are active, they are difficult to administer due to adverse events. Therefore, it is important to be mindful when treating these patients.

When treating with immunotherapies, off-target autoimmune events are concerning, states Pegram. More clinical trials are needed to discover the safest and most efficacious doses.

SELECTED
LANGUAGE


Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses challenges facing the treatment of patients with HER2-positive breast cancer.

Safety signals remain to be a big challenge facing this patient population, explains Pegram. While TKIs are active, they are difficult to administer due to adverse events. Therefore, it is important to be mindful when treating these patients.

When treating with immunotherapies, off-target autoimmune events are concerning, states Pegram. More clinical trials are needed to discover the safest and most efficacious doses.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Community Practice Connections™: Evolving Applications for PARP Inhibitors in Ovarian Cancer: Building on a Solid FoundationAug 15, 20191.5
Publication Bottom Border
Border Publication
x